Global Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Treatment Market Expected to Reach USD 89.96 Million by 2033 with a 12% CAGR, Driven by Advances in Genetic Medicine

Global Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Treatment Market

The global molybdenum cofactor deficiency type-A (MoCoD-A) treatment market, valued at USD 25 million in 2022, is set for substantial growth, projected to achieve approximately USD 89.96 million by 2033. This growth, corresponding to a CAGR of 12% during the forecast period from 2023 to 2033, is primarily driven by an enhanced understanding of the underlying biology of the condition and advancements in genetic and precision medicine. The market demonstrated a CAGR of 7.5% during the historical period from 2018 to 2022.

Molybdenum cofactor deficiency type A (MoCoD-A) is a rare genetic disorder that impairs the body’s ability to utilize molybdenum, a vital mineral, leading to deficiencies in several critical enzymes. This deficiency can result in severe neurological complications, including seizures, developmental delays, and intellectual disabilities. As awareness of MoCoD-A increases, there is a growing demand for effective treatment options that can mitigate its debilitating effects.

The anticipated growth in the MoCoD-A treatment market is supported by ongoing research initiatives focused on developing targeted therapies and improving patient care. Advances in genetic medicine and precision therapies hold promise for more effective interventions, ultimately enhancing the quality of life for individuals affected by this rare disorder. This market growth highlights the critical importance of continued investment in research and innovation in the field of rare genetic diseases.

Molybdenum cofactor deficiency type A (MoCoD-A) is a rare genetic disorder that affects the body’s ability to use molybdenum, an essential mineral, leading to a deficiency in several important enzymes. This deficiency can cause severe neurological problems, including seizures, developmental delays, and intellectual disabilities.

There are treatments available that can help manage the symptoms of the condition. These treatments typically involve a combination of medications and supportive therapies to address the various neurological and developmental issues associated with the disorder.

Market Competition

Key players in the molybdenum cofactor deficiency type-A (MoCoD-A) treatment market are BridgeBio Pharma, Origin Biosciences, Orphatech Pharmaceuticals, GmbH, Bayer, Agios Pharma, Daiichi Sankyo, Ohm Oncology, Aslan Pharmaceuticals, Pfizer, Inc. and Sun Pharmaceutical Industries Ltd.

• BridgeBio Pharma has developed a drug called BBP-871 for the treatment of MoCoD-A. BBP-871 is a recombinant form of human sulfite oxidase, which is an enzyme that is deficient in individuals with MoCoD-A. By replacing the missing enzyme, BBP-871 can potentially help to restore the body’s ability to process sulfur-containing amino acids and prevent the buildup of toxic metabolites that can cause neurological damage.
• Orphatech Pharmaceuticals, a key player in the market for molybdenum cofactor deficiency type-A (MoCoD-A) treatment is maximizing the use of technological advancement to innovate medications.

Key Companies Profiled

• BridgeBio Pharma
• Origin Biosciences
• Orphatech Pharmaceuticals, GmbH
• Bayer AG
• Agios Pharma
• Daiichi Sankyo
• Ohm Oncology
• Aslan Pharmaceuticals
• Pfizer, Inc.
• Sun Pharmaceutical Industries Ltd.

A Full Report Overview

Key Segments Profiled in the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Treatment Industry Survey

Drug Class:

• Sulfocysteine
• Fosdenopterin
• Pyridoxine

Route of Administration:

• Oral
• Parenteral
• Subcutaneous
• Topical

Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube